Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device
First Claim
1. A method for in vivo positive blood vessel remodeling in a patient with vascular disease, comprising implanting into a blood vessel of a patient a medical device having a coating comprising one or more layers of a matrix, one or more pharmaceutical substances, and one or more ligands designed to bind to a specific molecule on the cell membrane of a target cell.
2 Assignments
0 Petitions
Accused Products
Abstract
A medical device for implantation into vessels or luminal structures within the body is provided, which stimulates positive blood vessel remodeling. The medical device, such as a stent and a synthetic graft, is provided with a coating with a pharmaceutical composition containing a controlled-release matrix and one or more pharmaceutical substances for direct delivery of drugs to surrounding tissues. The coating on the medical device further comprises one or more barrier layers, and a ligand such as a peptide, an antibody or a small molecule for capturing progenitor endothelial cells in the blood contacting surface of the device for restoring an endothelium at the site of injury. In particular, the drug-coated stents are for use, for example, in balloon angioplasty procedures for preventing or inhibiting restenosis.
150 Citations
34 Claims
- 1. A method for in vivo positive blood vessel remodeling in a patient with vascular disease, comprising implanting into a blood vessel of a patient a medical device having a coating comprising one or more layers of a matrix, one or more pharmaceutical substances, and one or more ligands designed to bind to a specific molecule on the cell membrane of a target cell.
- 19. A method of treating mammals with restenosis or artherosclerosis, comprising implanting into a patient a medical device comprising a coating for controlled release of one or more pharmaceutical substances to adjacent tissues, wherein the coating comprises a biocompatible matrix, one or more pharmaceutical substances, and at least one ligand for capturing and immobilizing genetically modified target cells on the blood contacting surface of the medical device.
-
27. A method for in vivo positive blood vessel remodeling comprising:
implanting into a blood vessel of a patient a medical device having a coating comprising at least one layer of a matrix selected from the group consisting of a non-polymer porous structure, tropoelastin, elastin, and crossed-linked tropoelastin matrix, or combinations thereof;
one or more pharmaceutical substances, and one or more ligands which bind to specific molecules on the cell membrane of a target cell;
wherein said target cell secretes a vasodilator substance.- View Dependent Claims (28, 29)
-
30. An implantable medical device having a luminal surface and a coating;
- wherein the coating comprises a non-polymer matrix;
one or more pharmaceutical substances and a ligand attached to said matrix and configured to attach to circulating progenitor cells on the luminal surface of the device when implanted into a blood vessel of a patient. - View Dependent Claims (31, 32, 33, 34)
- wherein the coating comprises a non-polymer matrix;
Specification